Inhibitory effects of various spasmolytics on the vagal afferent gastric excitatory response in cats.
The inhibitory effects of atropine, cimetropium, pirenzepine and N-butylscopolamine on the vagal afferent gastric excitatory response in cats under anesthesia with pentobarbital sodium and infusion of gallamine were examined. Electrical stimulation of vagal trunk in left side (10 Hz in frequency, 3 msec in duration, 15 V in intensity and for 10 sec) caused an initial gastric excitatory response during the period of stimulation followed by a late excitatory gastric response after stimulation in normal cats. The initial response was inhibited by atropine (100 microg/kg, i.v.) and hexamethonium (10 mg/kg, i.v.), while the late response was inhibited by atropine but not by hexamethonium (10 mg/kg, i.v.). In chronic supranodose vagotomized cats 11-15 days after the operation, stimulation of the vagal trunk caused a late gastric excitatory response after the stimulation period, which was inhibited by atropine (100 microg/kg, i.v.) but not by hexamethonium (10 mg/kg, i.v.). The two types of gastric responses in normal cats have been defined as follows: the initial gastric excitatory response (atropine- and hexamethonium- sensitive) is due to activation of vagal efferent fibers and the late gastric excitatory response (atropine-sensitive and hexamethonium-resistant) is due to activation of vagal afferent fibers. ED50 values of atropine, cimetropium, pirenzepine and N-butylscopolamine in inhibiting the vagal afferent gastric response were 7.2 microg/kg (n=4), 2.4 microg/kg (n=6), 82.6 microg/kg (n=3) and 93.0 microg/kg (n=4), respectively. The inhibitory effects of atropine and cimetropium on the vagal afferent gastric excitatory response (hexamethonium-resistant) were more potent than those of pirenzepine and N-butylscopolamine. These results suggested that the potent inhibitory effects of cimetropium and atropine on the vagal afferent gastric response may involve a potent spasmolytic effect.
Kurahashi
K
K
Pharmacology Division, Radioisotope Research Center, Kyoto University, Japan.
Iwamoto
M
M
Aoki
S
S
Kawaguchi
A
A
Jino
H
H
Usui
H
H
Nishiwaki
H
H
Kitagawa
H
H
D000818:Animals; D001285:Atropine / Q000494:pharmacology; D002086:Butylscopolammonium Bromide / Q000494:pharmacology; D002415:Cats; D004558:Electric Stimulation; D005260:Female; D008297:Male; D009475:Neurons, Afferent / Q000187:drug effects* / Q000502:physiology; D009476:Neurons, Efferent / Q000187:drug effects* / Q000502:physiology; D010276:Parasympatholytics / Q000494:pharmacology*; D010890:Pirenzepine / Q000494:pharmacology; D012602:Scopolamine Derivatives / Q000494:pharmacology; D013270:Stomach / Q000294:innervation*; D014630:Vagus Nerve / Q000187:drug effects* / Q000502:physiology
D010276:Parasympatholytics; D012602:Scopolamine Derivatives; C016859:cimetropium; D002086:Butylscopolammonium Bromide; D010890:Pirenzepine; D001285:Atropine